Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1579 of 5804
-
New hope for NF1 patients: targeted drug shrinks inoperable tumors in early trial
Disease control OngoingA Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects with Neurofibromatosis Type 1 (NF1) and Inoperable…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New antibiotic shows promise against superbug blood infections
Disease control CompletedA Phase 3, Multicenter, Randomised, Controlled, Open-Label Study to demonstrate noninferiority of temocillin (unauthorized investigational medicinal product IMP in Spain, but authorized in Belgium and UK) vs a carbapenem antibiotic (meropenem) in adults with bacteraemia due to th…
Phase: PHASE3 • Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Fasting without fasting: diet mimicry may ease colitis symptoms
Symptom relief Recruiting nowThe purpose of this study is to see how a diet that mimics fasting effects inflammation in patients with mild to moderate Ulcerative Colitis (UC). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (g…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Smart spinal device aims to quiet chronic pain
Symptom relief Recruiting nowThe purpose of this study is to test and evaluate novel treatment delivery of ECAP-controlled closed loop SCS through the incorporation of new software and/or hardware features for patients with the Evoke System.
Phase: NA • Sponsor: Saluda Medical Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can primary care teams tackle opioid addiction and depression together?
Disease control CompletedCollaborative care for mental health is increasingly common, but most primary care practices have not embraced similar models for opioid use disorder (OUD). This study will refine and test a collaborative care model for patients with opioid use disorder (OUD) and depression, anxi…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Which drug first? new trial aims to improve survival in tough colorectal cancer
Disease control OngoingThe association of doublet chemotherapy (FOLFOX and FOLFIRI) and anti-EGFR-moAbs (panitumumab or cetuximab) is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients, especially with left-sided primary tumour. In RAS wt mCRC patients refract…
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo shows promise against blood cancer in japanese trial
Disease control OngoingThis is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Biosciences Japan GK • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Glow-in-the-Dark dye could help surgeons see hidden cancer cells
Diagnosis Recruiting nowAssess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of De…
Phase: PHASE1, PHASE2 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New antibody drug shows promise in fighting advanced cancers
Disease control OngoingThis is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
Phase: PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise for kidney disease patients
Disease control Recruiting nowTo determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor b…
Phase: PHASE2 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New shot could stop cold hives
Disease control CompletedPrimary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine Secondary Objectives: To demonstrate the efficacy of du…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC
-
New heart study aims to cut unnecessary pacemaker implants by half
Knowledge-focused OngoingPrevious experience with cardiac resynchronization therapy (CRT) candidates suggests that selection of these patients can be improved. Current clinical guideline approaches are mainly too unspecific and lead to a high non-responder rate of 30-40%, which causes a burden on health …
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a wakefulness drug beat daytime sleepiness in Prader-Willi syndrome?
Symptom relief CompletedThe primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi syndrome (PWS) ages 6 to 65 years.
Phase: PHASE2 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Sickle cell drug mitapivat faces Long-Term safety check in small study
Disease control OngoingBackground: Sickle cell disease (SCD) is a disorder that causes episodes of acute pain and progressive organ damage. Ways to manage SCD have evolved slowly. Treatments do not always work. Researchers want to see if a drug called mitapivat can help people with SCD. Objective: T…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New combo pill aims to crush stubborn high cholesterol
Disease control CompletedPrimary Objective: To demonstrate the superiority of the single pill combination (SPC) ezetimibe 10 mg/rosuvastatin 10 mg (E10/R10) compared to rosuvastatin 10 mg (R10), in the reduction of low density lipoprotein cholesterol (LDL-C) after 8 weeks. Secondary Objectives: * To e…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Talking together: couples program helps pregnant moms with HIV stay healthy
Disease control CompletedThe objective of this study is to test the preliminary efficacy of a novel couples' counseling intervention to promote the health of pregnant women living with HIV in Lusaka, Zambia.
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can better talks help kids with cancer have a gentler end of life?
Knowledge-focused CompletedThis prospective cluster-randomized trial examines the efficacy of a novel communication intervention delivered by trained physician and nurse dyads to parents of children with cancer within the clinicians' practice, to foster alignment of the goals of treatment. The investigator…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Parents key to fighting obesity in childhood cancer survivors
Disease control OngoingPediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term h…
Phase: NA • Sponsor: University of South Florida • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for rare lung cancer mutations? dacomitinib under study
Disease control OngoingThis is a single center and exploratory study, aiming to analyze the efficacy and safety of dacomitinib-a pan-HER and irreversible TKI in subjects with diagnosed stage IIIB/IV or recurrent NSCLC. All subjects will have tumors that test positive for at least one uncommon EGFR acti…
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:07 UTC